FY2024 Earnings Forecast for BPMC Issued By Zacks Research

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at Zacks Research issued their FY2024 earnings per share (EPS) estimates for Blueprint Medicines in a research note issued to investors on Monday, November 18th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will earn ($3.87) per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.66) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q4 2024 earnings at ($0.86) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($2.37) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.07 EPS and FY2026 earnings at $0.25 EPS.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. Blueprint Medicines’s revenue for the quarter was up 126.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.20) EPS.

A number of other analysts have also commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Monday, November 18th. Barclays raised their target price on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday, July 29th. Baird R W upgraded shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Finally, UBS Group began coverage on Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $122.11.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $94.15 on Thursday. Blueprint Medicines has a 1-year low of $66.61 and a 1-year high of $121.90. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The business has a 50 day moving average price of $90.36 and a 200 day moving average price of $98.60. The company has a market capitalization of $5.98 billion, a P/E ratio of -44.62 and a beta of 0.59.

Institutional Trading of Blueprint Medicines

Several hedge funds have recently bought and sold shares of the business. Hsbc Holdings PLC purchased a new position in Blueprint Medicines during the 2nd quarter worth $1,060,000. Comerica Bank grew its stake in Blueprint Medicines by 2,582.9% in the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock worth $1,028,000 after buying an additional 10,435 shares in the last quarter. Federated Hermes Inc. grew its position in Blueprint Medicines by 27.8% during the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock valued at $6,721,000 after acquiring an additional 13,579 shares during the last quarter. SG Americas Securities LLC boosted its position in Blueprint Medicines by 82.8% during the second quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock valued at $2,337,000 after buying an additional 9,819 shares during the period. Finally, Vanguard Group Inc. grew its position in Blueprint Medicines by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 6,309,977 shares of the biotechnology company’s stock worth $598,564,000 after acquiring an additional 195,007 shares during the last quarter.

Insider Transactions at Blueprint Medicines

In related news, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the transaction, the insider now directly owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.